微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 48.2% | -0.81% | 0.16% | 77/158 | -2.04% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 48.12% | -1.52% | 0.74% | 78/158 | 14.94% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 47.77% | -4.48% | -0.43% | 74/158 | 32.08% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 47.97% | 0.29% | -1.28% | 81/158 | 51.81% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 48.6% | -0.01% | -0.55% | 81/158 | 22.66% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 48.87% | -2.26% | -2.29% | 80/158 | 33.21% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 50.01% | -2.5% | 4.54% | 76/158 | 51.68% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 47.84% | 1.17% | -1.57% | 83/158 | 51.58% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 48.6% | 4.48% | -2.79% | 83/158 | 32.59% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 50% | 9.25% | -2.53% | 79/158 | 38.52% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 51.29% | 17.77% | 8.48% | 73/158 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 47.28% | -1.79% | 1.65% | 88/158 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 46.52% | -6.19% | 1.65% | 85/158 | 6.03% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 45.76% | -10.79% | 5.08% | 86/158 | 21.28% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 43.55% | -15.89% | -9.53% | 88/158 | 54.44% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 48.14% | -11.96% | -2.91% | 87/158 | 55.28% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 49.59% | -11.24% | -3.34% | 76/158 | 46.93% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 51.3% | -7.89% | -0.94% | 77/158 | 47.39% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 51.78% | -6.07% | -5.31% | 69/158 | 54.24% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 54.69% | -8.27% | -2.12% | 72/158 | -147.15% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 55.87% | -6.55% | 0.32% | 60/158 | 56.61% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 55.69% | -7.94% | 1.02% | 62/158 | 54.34% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 55.13% | -6.76% | -7.53% | 53/158 | 55.43% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 59.62% | 2.08% | -0.28% | 61/158 | -1232.32% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 59.79% | 2.6% | -1.17% | 48/158 | 55.43% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 60.49% | 3.77% | 2.32% | 46/158 | 55.42% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 59.12% | 2.66% | 1.23% | 44/158 | 51.19% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 58.4% | -0.92% | 0.22% | 58/158 | -209.94% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 58.27% | -0.21% | -0.04% | 44/158 | 54.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 58.29% | 1.85% | 1.22% | 42/158 | 53.57% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 57.59% | 4.08% | -2.29% | 43/158 | 54.1% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 58.95% | 9.01% | 0.94% | 43/158 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 58.39% | 8.55% | 2.02% | 32/158 | 49.3% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 57.24% | 7.07% | 3.43% | 33/158 | 48.06% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 55.34% | 7.16% | 2.34% | 30/158 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 54.07% | 8.21% | 0.52% | 40/158 | 48.52% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 53.8% | 6.24% | 0.63% | 26/158 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 53.46% | 5.8% | 3.53% | 30/158 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 51.64% | 4.72% | 3.34% | 25/158 | 43.86% | 贝达药业 | 97.01% | 行业排名> |